Wuxi Biologics: Expects net profit to increase by 13.00%-34.00% year-on-year by 2025.

Watson Bio announced that it is expected to achieve a net profit of 160 million to 190 million yuan in 2025, representing a year-on-year growth of 13.00% to 34.00%; the net profit after deducting non-recurring gains and losses is expected to be 85 million to 99 million yuan, representing a year-on-year decrease of 22.00% to 9.00%; operating income is expected to be 2.4 billion to 2.43 billion yuan, compared to 2.821 billion yuan in the same period last year. During the reporting period, the overall domestic and international vaccine markets are still in a downward cycle, with the company's total vaccine product income decreasing by about 8% compared to the same period last year. The decrease in domestic vaccine product income has narrowed and stabilized, while foreign vaccine product income continues to grow, with export vaccine product income increasing by about 35% compared to the same period last year. The company continues to strengthen cost reduction and efficiency improvement measures, continuously improving operational management capabilities, and achieving a growth in net profit attributable to shareholders of the listed company compared to the same period last year.